Marty Schenker

Cooley advised Beam Therapeutics, a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines, on its agreement with Verve Therapeutics to sell its opt-in rights to co-develop and co-commercialize base-editing programs for cardiovascular disease to Eli Lilly and Company.

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Successfully represented Pacific Gas and Electric in its bankruptcy confirmation trial, widely believed to be one of the most complex confirmation proceedings in the history of the US Bankruptcy Courts. The case concluded with the confirmation of PG&E's bankruptcy plan, enabling the company to emerge from bankruptcy.

Cooley is advising biopharmaceutical company Medivation on its agreement to sell to Pfizer for approximately $14 billion. The transaction is expected to close in the third or fourth quarter. Prior to the announced agreement, Cooley also advised Medivation as the target of a hostile takeover bid by Sanofi.

Successfully represented Qualcomm in its global patent-licensing dispute with Nokia concerning Qualcomm's cellular communications technology. The case settled favorably for Qualcomm at the start of trial, resulting in a 15-year multibillion-dollar license agreement between Qualcomm and Nokia.